opportunity analysis

ImmunoCellular Therapeutics to Present at the Lytham Partners Virtual Investor Conference on October 11, 2017 at 2:00pm ET


Live presentation will take place on October 11, 2017 at 2:00pm ET / 11:00am PT; Replay available on demand


October 3, 2017 - ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on Stem-to-T-Cell research, announced today that Anthony Gringeri, Ph.D., President and Chief Executive Officer, Steven Swanson, Ph.D., Sr. VP, Research, and David Fractor, Chief Financial Officer, will present at the Lytham Partners Virtual Investor Conference on Wednesday, October 11, 2017 at 2:00 p.m. ET (11:00 a.m. PT). The conference is a virtual event that is available over the internet. Interested parties may participate by clicking on either of the links cited below at the time of the conference.

Date: Wednesday, October 11, 2017

Time: 2:00 pm ET / 11:00am PT

Webcast: http://investors.imuc.com/events.cfm or IMUC Live Presentation

Interested parties around the world may view the live investor presentation and ask the speakers questions in real-time. A replay of the presentation will be available on demand following the conclusion of the live event at http://investors.imuc.com/events.cfm or by accessing the live event here.

The presentation will contain forward-looking statements. The information provided on the presentation is accurate only as of the time of the virtual presentation, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors. To learn more about ImmunoCellular, please visit www.imuc.com.

ImmunoCellular Therapeutics, Ltd. Contact: Jane Green (415) 348-0010 direct (415) 652-4819 mobile jane@jmgcomm.com

Investor Relations Contact: Lytham Partners, LLC Joe Dorame, Robert Blum, or Joseph Diaz (602) 889-9700 imuc@lythampartners.com